10 AI-Analyzed Biotech Signals
for $9

Filing: UX111 BLA resubmission accepted; September 19 PDUFA

Ultragenyx is the cleanest September binary in the screen: the FDA accepted the UX111 BLA resubmission and set a September 19, 2026 PDUFA action date for Sanfilippo syndrome Type A, a rare pediatric indication with no approved therapy. The August 5 10-Q showed $125 million of cash plus $167 million of marketable securities at June 30, and SEC data shows six Form 4 filings since June 1. This is high-volatility small/mid-cap biotech, but the catalyst is current, named, and near-term.

Filing: Zilganersen Priority Review and first independent neurology launch setup

Ionis has a September 22, 2026 FDA target action date for zilganersen in Alexander disease, and management has framed the filing as a potential first independent neurology launch. The July 29 10-Q showed roughly $350.1 million of cash and $1.70 billion of short-term investments at June 30, giving the company launch optionality without an obvious near-term financing overhang. The caveat: 25 Form 4 filings since June 1 mean the insider-tape is noisy rather than a simple accumulation signal.

Filing: Zilurgisertib Priority Review for FOP; September 26 PDUFA

Mirum and Incyte's zilurgisertib program has a September 26, 2026 PDUFA date in fibrodysplasia ossificans progressiva, and Mirum's Q2 balance sheet showed $330.7 million of cash plus $107.6 million of short-term investments. SEC data shows 23 Form 4 filings since June 1, so BioAlpha treats this as a catalyst-plus-liquidity setup rather than an insider-accumulation setup. The signal remains positive because the FDA date is specific, priority-reviewed, and attached to a rare disease market where first/early entrants can reprice quickly.